Targovax – Therapeutic cancer vaccines

Targovax is an innovation driven specialist in immuno-oncology.

Webcast of the third quarter 2016 results presentation Thursday 17 November - A presentation by Targovax's CEO, Øystein Soug, to investors, analysts and the press will take place in Oslo at 10:00 CET.

Read more

Even in late stage cancer patients with low immunogenic tumor types, our virus-based immunotherapy can reinstate the immune system’s ability to recognize and attack cancer cells. In addition, studies with our peptide-based Immunotherapy have shown immune responses in difficult to treat RAS cancer patients.

Read more

Ringing the bell at the Oslo Axess stock exchange to announce the start of public trading of Targovax. On 8 July Targovax was listed on the Oslo Axess stock exchange. A prospectus for the listing and a complete description of all conditions for the subsequent offering can be downloaded here.

Read more
  • Targovax ASA: Third quarter 2016 results

    November 17, 2016

    Oslo, Norway, 17 November 2016 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces its third quarter 2016 results. A meeting for investors, analysts and pre (...)

    Read more
  • Targovax to present at forthcoming conference

    November 16, 2016

    Oslo, 16 November 2016: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present a corporate overview at the fol (...)

    Read more
  • Targovax granted European Patent for ONCOS platform lead product, ONCOS-102

    November 10, 2016

    Extends protection following grant of ONCOS-102 US patent in May

    Oslo, 10 November 2016: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, today announces the grant  (...)

    Read more
  • Targovax ASA: Invitation to third quarter 2016 results presentation Thursday 17 November

    November 8, 2016

    Oslo, Norway, 8 November 2016 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing and commercializing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, will announce its third quarter 2016 results on Thursday, 17 November 2016. A presentation by (...)

    Read more
  • Targovax announces appointment of Oystein Soug as CEO

    November 2, 2016

    Oslo, 2 November, 2016: Targovax ASA ("Targovax" or "the Company"; OSE:TRVX), a clinical stage company focused on developing and commercializing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, today announces that Gunnar Gårdemyr, the Company's Chief Executive Offic (...)

    Read more
  • Career: Director/Sr Manager Clinical Development

    October 24, 2016

    To ensure high quality in all our clinical studies, we want to hire a new Director/Sr Manager in the Clinical Department with experiences in managing clinical trials and with in-depth knowledge of clinical development.

    Read more

    Read more